Get access

Management of anticoagulation during dermatosurgical procedures in Germany – results from a cross-sectional study

Authors

  • Alexander Nast,

    1. Division of Evidence-Based Medicine (dEBM), Department of Dermatology, Venereology and Allergology, Charité– University Medicine Berlin, Germany
    2. Division of Dermatosurgery, Department of Dermatology, Venereology and Allergology, Charité– University Medicine Berlin, Germany
    Search for more papers by this author
  • Henriette Ernst,

    1. Division of Evidence-Based Medicine (dEBM), Department of Dermatology, Venereology and Allergology, Charité– University Medicine Berlin, Germany
    Search for more papers by this author
  • Stefanie Rosumeck,

    1. Division of Evidence-Based Medicine (dEBM), Department of Dermatology, Venereology and Allergology, Charité– University Medicine Berlin, Germany
    Search for more papers by this author
  • Ricardo Erdmann,

    1. Division of Evidence-Based Medicine (dEBM), Department of Dermatology, Venereology and Allergology, Charité– University Medicine Berlin, Germany
    Search for more papers by this author
  • Birte Sporbeck,

    1. Division of Evidence-Based Medicine (dEBM), Department of Dermatology, Venereology and Allergology, Charité– University Medicine Berlin, Germany
    2. Division of Dermatosurgery, Department of Dermatology, Venereology and Allergology, Charité– University Medicine Berlin, Germany
    Search for more papers by this author
  • Joachim W. Fluhr

    1. Division of Dermatosurgery, Department of Dermatology, Venereology and Allergology, Charité– University Medicine Berlin, Germany
    Search for more papers by this author

Priv.-Doz. Dr. Alexander Nast, Division of Evidence-Based Medicine (dEBM), Department of Dermatology, Venereology and Allergology, Charité– University Medicine Berlin, Charitéplatz 1, D-10117 Berlin, Germany, Tel.: +49-30-450-618313, Fax: +49-30-450-518977, E-mail: alexander.nast@charite.de

Summary

Background: Treatment with antiplatelet drugs (APD) and vitamin K antagonists (VKA) can be a challenge during the management of dermatosurgical interventions.

Methods: We performed a cross-sectional study on the perioperative management of APD and VKA in dermatological private practices and clinics in Germany, using anonymized, standardized questionnaires.

Results: 233 responses were evaluated (response rate 37 %). Skin biopsies are performed in 82.7 % of offices and in 90.8 % of clinics despite treatment with VKA. Small excisions are done in 62.5 % of offices and 76.9 % of clinics during treatment with VKA, for large excision this applies to 11.9 % of offices and 33.8 % of clinics. Low-dose treatment with APD (#100 mg) does not hinder 80.4 % of private practices and 89.2 % of clinics to perform small excisions as well as 36.3 % and 53.8 %, respectively, to perform large excisions. Of private practitioners 67.3 % and 83.1 % of clinic-based dermato-surgeons do not consider high-dose APD a contraindication for small excisions, and 25.0 % and 41.5 %, respectively, for large excisions. Most frequently switching to heparin is performed 6–8 days prior to surgery and switching back 0–2 days after surgery.

Conclusions: Large differences in the perioperative management of anticoagulant therapy during dermatosurgical procedures have been identified. Further studies and guidelines should be developed.

Ancillary